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34 
35 Abstract 
36 This study examined the underlying mechanisms by which whey protein isolate (WPI) affects  
37 energy balance. C57BL/6J mice were fed a diet containing 10% kJ fat, 70%kJ carbohydrate (35%kJ 
38 sucrose) and 20% kJ casein or WPI for 15 weeks. WPI reduced weight gain, cumulative energy 
39 intake and dark phase oxygen consumption (V02) compared to casein fed mice (P<0.05), but had no 
40 significant effects on body composition, meal size/number, water intake or respiratory exchange 
41 ratio (RER). Plasma levels of insulin, triacylglycerides (TAG), leptin, glucose, and glucagon-like 
42 peptide 1 remained unchanged. Notably, WPI reduced stomach weight and both length and weight 
43 of the small intestine (P<0.05). WPI reduced gastric expression of Wnt5a (P<0.01) and Frizzled 4 
44 (Fzd4) (P<0.01) with no change in expression of receptor tyrosine kinase-like orphan receptor 2 
45 (Ror2) and low density lipoprotein receptor-related protein 5 (Lrp5). In the ileum, WPI increased 
46 Wnt5a mRNA expression (P<0.01) and caused a trend towards increased expression of Fzd4  
47 (P=0.094), with no change in Ror2 and Lrp5. These genes were unresponsive in the duodenum. 
48 Among nutrient responsive genes, WPI specifically reduced ileal mRNA expression of peptide YY 
49 (P<0.01) and fatty acid transporter 4 (P<0.05), and decreased duodenal mRNA expression of the 
50 insulin receptor (P=0.05), with a trend towards a decreased expression of sodium-glucose co- 
51 transporter 1 (P=0.07). The effects of WPI on intestinal Wnt signalling may explain how WPI  
52 affects gastrointestinal structure and function and in turn energy intake and balance. 
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68 Introduction 
69 Whey proteins are a by-product of cheese manufacture. These dietary proteins have gained 
70 considerable interest in recent years in relation to their health benefits, which include reduction in 
71 energy intake and body weight, and improvements to insulin sensitivity (1; 2) . However, more 
72 research is required to assess if whey protein effects are dependent upon macronutrient composition 
73 in the diet, as demonstrated previously for high whey protein enriched diets
(3)
, as this will allow 
74 creation of diets with the optimum macronutrient combination that enhances specific whey protein 
75 effects on human health. Additionally, this work may also uncover the mechanisms underpinning 
76 the effects of these proteins. 
77 We have previously shown that intake of 20% energy whey protein isolate (WPI) reduces 
78 weight gain, fat mass and increases lean mass in mice fed a high fat (45% by energy) diet (4; 5) . In 
79 contrast, on a low fat diet (e.g. 10% fat by energy), an impact on energy balance has been observed 
80 when a high whey protein content was used in the test diets, where the protein derived energy 
81 content was far beyond the adequate range (14-25%). Moreover, where effects were found, the 
82 underlying mechanisms have not been elucidated. For instance, mice fed a diet containing 30% 
83 energy from whey proteins and 10% energy from fat reduced energy intake and weight gain by 1 
84 week compared to similar diet but with either soy or gluten as the protein source
(6)
. A reduction in 
85 cumulative energy intake was observed in rats between 5 to 10 weeks when fed a diet providing 
86 42% energy from proteins (26% whey and 16% albumin) in comparison to a similar diet but with 
87 the whey replaced by either albumin or soy protein with albumin
(7)
. In contrast, when the dietary 
88 protein derived energy content was reduced to 15 or 25%, with fat derived energy content was 
89 maintained around 9 and 15%, respectively, whey proteins did not affect energy intake and body 
90 weight gain(8; 9) . Interestingly, the latter studies assessed food intake only for 2 or 7 week duration, 
91 in comparison to the high whey protein study, where the reduction in energy intake occurred by 
92 week 5 and continued up to 10 weeks
(7)
. Thus, the discrepancy in the data could be due to the test 
93 duration, where a longer duration is required when adequate protein derived energy content is used 
94 in test diets. Thus, the purpose of this study was to assess if WPI at 20% energy content in a 10% 
95 energy fat diet alters energy balance and where there is an effect, to explore the mechanisms 
96 involved. The study lasted for 15 weeks in consideration the previous published data showing that 
97 whey protein (at adequate range) did not affect energy balance up to 7 weeks(8; 9). 
98 
99 Materials & Methods 
100 
101 Animals & diets 
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102 All procedures involving animals were approved by the University College Cork Animal  
103 Experimentation Ethics Committee (~201 1/005) and were licensed under the Cruelty to Animals 
104 Act 1876. Three week old C57BL/6J male mice (Harlan; UK) were singly housed and had ad 
105 libitum access to food and water throughout the trial. Mice were initially fed a diet containing 
106 10%kJ fat, 70%kJ carbohydrate (35%kJ sucrose) and 20%kJ casein (LF-CAS; #D12450; Research 
107 Diets, USA) during the acclimatisation period lasting three weeks. 
108 
109 Experimental protocol 
110 Following acclimatisation, singly housed mice were separated into two weight matched dietary 
111 groups and provided either the LF-CAS diet or a comparable LF with WPI (Alacen
tm
 895 NZMP, 
112 Auckland, New Zealand) (LF-WPI) for a total of 15 weeks (n = 8). Further details of the diet 
113 composition can be found in the supplementary table 1. Body weight and energy intake were 
114 measured weekly. In addition, at week 14, feeding behaviour and metabolic activity were measured 
115 using TSE Phenomaster system compromising 8 test cages and one reference cage (Bad Homburg, 
116 Germany). Mice were housed individually in the test cages. After a 2 day acclimatisation period, 
117 metabolic parameters were measured on the 3
rd
 day. Sensors recorded metabolic parameters in 
118 cages sequentially with each cage being analysed for one minute, such that data collected over 24h 
119 period corresponded to 9 minute intervals for the 8 test cages and one reference cage. Body 
120 composition was determined by NMR using a Bruker minispec LF50H (Bruker optics, Germany) at 
121 the end of the study, following a 6-8h fast. Subsequently, mice were anesthetised and blood was 
122 collected. The mice were then sacrificed by cervical dislocation. Tissues of interest were excised 
123 and weighed. Small intestinal luminal contents were removed by mechanical expulsion and the  
124 tissue length was determined. The tissue was weighed and 2cm sections from the proximal and 
125 distal parts of the intestine that were 2cm away from the start and end of the intestine, respectively, 
126 were excised for analysis of gene expression in the duodenum and ileum. All tissues were  
127 immediately snap frozen in liquid nitrogen. Plasma and tissue samples were stored at -80
o
C until 
128 analysis. 
129 
130 Biochemical analysis 
131 Blood collected into vacutinater EDTA tubes (BD; USA) from anesthetised mice (ketamine; 
132 65mg/kg, xylazine; 1 3mg/kg), was treated with Diprotin A and Aprotinin as described previously (4) 
133 to protect plasma peptides against proteolytic degradation. Plasma was isolated by centrifugation at 
134 2000rpm and 4
o
C for 15 mins, and was analysed using colorimetric assay kits to determine plasma 
135 concentrations of glucose (Calibochem, Germany) and TAG (LabAssay TAG, Wako Chemicals, 
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136 USA). ELISA kits were used determine plasma concentrations of glucagon-like peptide 1 (GLP-1) 
137 (Millipore, USA), leptin and insulin (Crystal Chem, USA). Homeostasis model assessment of  
138 insulin resistance (HOMA-IR) was calculated as previously detailed
(4)
. 
139 
140 Tissue gene expression 
141 Total RNA was isolated from tissues of interest (epididymal adipose tissue, liver, skeletal muscle, 
142 duodenum and ileum) using RNeasy mini kits (Qiagen, Germany) with subsequent DNase treatment 
143 to prevent genomic DNA contamination. Duodenal and ileal total RNA was isolated from  
144 representative intact tissue segments. Complementary DNA was synthesised from 1µg of isolated 
145 total RNA and subjected to Real-time qPCR analysis as described previously
(4)
. Primer sequences 
146 of target and reference genes are listed in supplementary table 2. Target gene mRNA expression 
147 was calculated using 
2-ΔΔCp,
 after normalising against the reference gene expression according to 
148 ΔΔCp= ΔCp target gene – ΔCp reference gene. Reference genes used were β-actin (adipose, liver, 
149 muscle, duodenum, ileum), YWHAZ (liver and duodenum, ileum) and 18-S (adipose). In instances 
150 where two housekeeping genes were used, a geometric mean was determined for normalisation. The 
151 gene expression is shown relative to the LF-CAS group. 
152 
153 Statistical analysis 
154 The data are presented as mean with standard error (SEM). Dietary treatment effects were analysed 
155 using unpaired T-tests. A two-way Repeated measures ANOVA with Bonferroni multiple 
156 comparisons was used to analyse bodyweight trajectories over the treatment periods. Mann- 
157 Whitney U tests were used to analyse non-parametric data. VO2 data were analysed by ANCOVA 
158 (SAS software version 9.3, USA) using total body weight as the co -variant as detailed 
159 previously
(10)
. Statistical significant was established at P ≤ 0.05, using Graphpad Prism (ver. 6), 
160 SAS software version 9.3, USA) and Minitab (ver. 15). 
161 
162 Results  
163 
164 Effect on weight gain and body composition 
165 Cumulative energy intake was significantly reduced in WPI fed mice over the first 13 weeks, and 
166 this was significant by week 11 onwards (Figure 1D; P < 0.05). In contrast, body weight gain was 
167 not significantly different at week 11 (6.17±0.28g in LF-WPI versus 7.05±0.54g in LF-CAS; 
168 P=0.17), but reached significance by week 12 (5.89±0.24g in LF-WPI versus 7.5±0.61g in LF-CAS; 
169 P<0.05). Although after 15 weeks of dietary intake, total body weight gain was significantly 
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170 reduced in the LF-WPI group compared to LF-CAS group (Figure 1B; P < 0.05), at this time point, 
171 there was no significant difference in either body weight or body composition (fat or lean mass %) 
172 between the two groups (Figure 1A and C). In correspondence with overall % body fat mass, the 
173 mass of both the subcutaneous and epididymal adipose tissue depots was not different between the 
174 LF-CAS and LF-WPI fed mice (Figure 2A). 
175 
176 Effect on energy intake and metabolism related parameters 
177 Further analysis of energy intake using TSE Phenomaster cages in week 14 (Table 2), showed a 
178 reduction in the dark-phase energy intake in the WPI group, although this was not significant. There 
179 were also no significant effects on the 24hr meal pattern, represented by meal number and size,  
180 RER and water intake but dark phase VO2 decreased by WPI and there was also a trend towards a 
181 decrease in VO2 during light phase (Table 2), which was revealed by analysis of metabolic data 
182 independent of body weights of the animals. 
183 
184 Effect on the gastrointestinal tract 
185 Mice fed WPI had reduced stomach and small intestine weights relative to casein controls after 15 
186 weeks of dietary treatment, which also corresponded with a concomitant reduction in small  
187 intestinal length (Figure 2). 
188 At a cellular level, WPI intake reduced gene expression of Wnt5a and Frizzled 4 (Fzd4) in the 
189 stomach but not the expression of receptor tyrosine kinase-like orphan receptor 2 (Ror2) and low 
190 density lipoprotein receptor-related protein 5 (Lrp5) (Figure 3A). In the ileum, WPI increased 
191 Wnt5a mRNA expression and caused a trend towards increased expression of Fzd4  
192 (P=0.094)(Figure 3C). The Wnt signalling associated genes in the duodenum did not respond to 
193 WPI (Figure 3B). However, in the same region, WPI intake caused a trend towards a decrease in 
194 gene expression of insulin receptor (IR) and sodium-glucose co-transporter 1 (SGLT-1)(Table 3) 
195 with no change in insulin receptor substrate 1 (IRS 1), glucose transporter 2 (GLUT2) or glucose- 
196 dependent insulinotrophic peptide (GIP)(Table 3). Cholecystokinin (CCK) gene expression was 
197 decreased by WPI but not significantly (Table 3). In the ileum, GLUT2 gene expression was  
198 increased by WPI, whilst fatty acid transporter 4 (FATP4) expression was decreased (Table 3). Ileal 
199 proglucagon expression was unaffected by WPI (Table 3), which correlated with plasma GLP-1 
200 level (Table 1), but PYY gene expression was reduced by WPI (Table 3). 
201 Investigation of the same tissues in a previous published study conducted in mice fed a similar LF- 
202 casein and LF-WPI diet for 7 weeks
(5)
, revealed that whilst the stomach weight was not different 
203 between the two groups (1.06 ± 0.10 in LF-WPI versus 1.00 ± 0.048 in LF-CAS; data relative to 
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204 LF-CAS set at 1.00), the intestinal weight in WPI fed mice was reduced relative to casein fed 
205 controls (0.73 ± 0.026 in LF-WPI versus 1.00 ± 0.035 in LF-CAS; P < 0.001; data relative to LF- 
206 CAS set at 1.00), as was the intestinal length (33.65 ± 0.38 cm in LF-WPI versus 35.64 ± 0.70 cm 
207 in LF-CAS; P < 0.05). 
208 
209 Effect on plasma hormones and metabolites and lipid metabolism related gene expression 
210 Although WPI did not affect plasma leptin (Table 1) and related epididymal gene expression 
211 (Figure 4), or plasma levels of TAG, insulin and glucose (Table 1), epididymal expression of fatty 
212 acid synthase (FASN), acetyl CoA carboxylase (ACC) and cluster of differentiation 36 (CD36) 
213 were significantly up-regulated in WPI fed mice compared to controls at 15 weeks (Figure 4).  
214 Additionally, lipoprotein lipase (LPL) gene expression also showed a trend towards an increase (P 
215 = 0.08)(Figure 4). Genes involved in insulin signalling (IR, GLUT4 and IRS-1), fatty acid 
216 catabolism (β3-AR, HSL, CPT1b and UCP-2) and adipogenesis (PPARγ) were unaltered by WPI 
217 intake (Figure 4). None of the insulin signalling or lipid metabolism related genes were altered by 
218 WPI intake in the muscle or liver (Supplementary table 3 and 4) with the exception of IRS-1, which 
219 showed a trend towards a decrease in the muscle in LF-WPI fed mice compared to controls 
220 (Supplementary table 3). 
221 
222 Discussion 
223 Our results showed that 15 weeks of WPI intake decreased weight gain, cumulative energy 
224 intake and dark phase metabolic activity (V02), which was accompanied by a reduction in stomach 
225 weight and intestinal length and weight in mice fed a low fat diet. WPI fed mice reduced cumulative 
226 energy intake by week 11. The dark phase metabolic activity, which was measured at week 14, also 
227 decreased in WPI fed mice compared to casein controls. The reduced body weight gain with WPI 
228 intake could thus be a consequence of the gradual decrease in cumulative energy intake occurring 
229 before the change in metabolic rate. Intestinal satiation/satiety-related CCK and proglucogon genes 
230 were unresponsive to the WPI intake, as was plasma GLP-1 level. Moreover, ileal expression of 
231 PYY, which reduces energy intake
(11)
, was significantly decreased in LF-WPI fed mice compared to 
232 LF-fed casein controls. These data suggest that modulation of the production of these satiety and 
233 satiation hormones was not the mechanism by which WPI reduces cumulative energy intake. 
234 The current data show that WPI intake reduces intestinal length. Given the association 
235 between reduction in the intestinal length and weight loss 
(12),
 here we sought to obtain further 
236 evidence supporting a link between WPI-induced changes in intestinal cellular activity and energy 
237 balance in mice by investigating nutrient responsive genes in the duodenum and ileum. Consistent 
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238 with a reduced nutrient contact with or passage through the intestinal cells, duodenum expression of 
239 IR and SLGT-1, that is responsive to glucose
(13)
, showed a trend towards a decrease in WPI fed 
240 mice compared casein controls. In the ileum, the cellular lipid transport protein FATP4
(14)
, and 
241 PYY, which are mainly responsive to availability of fat
(15)
, were both significantly decreased by 
242 WPI intake. Although duodenum mRNA expression of GLUT2, the protein product of which is  
243 predominantly found at the basolateral membrane of enterocytes
(16)
, was increased by WPI intake, 
244 one could argue based on other nutrient responsive genes that this change may represent a feedback 
245 mechanism to the lower availability of nutrients in the luminal side of the intestine. The gene  
246 expression data in the intestine are consistent with the changes in cumulative energy intake in the 
247 animals. 
248 To ascertain the timeframe of the change in intestine length and weight relative to energy 
249 intake, we investigated the same tissues in an earlier published study conducted in mice fed the 
250 same LF-CAS and LF-WPI diets, but where the study was terminated at week 7
(5)
 . In that study, by 
251 week 7, mice fed with WPI consumed a similar energy content to their casein counterparts, and had 
252 reduced intestinal weights and lengths similar to the present study. This suggests therefore that the 
253 reduction in cumulative energy intake, which reached significance compared to casein fed mice by 
254 week 11, occurred after the morphological change in the intestine. It is noteworthy that obese ob/ob 
255 mice have longer intestines
(17)
 and that the development of high fat diet-induced obesity in mice 
256 also increases villus lengths and cells per villus
(18)
. Moreover, recent study showed that WPI intake 
257 reduced growth-related parameters within the first week of diet intake
(19)
. The current data also 
258 show that WPI intake reduced stomach weight in mice. In contrast, in our previous published 7  
259 week study, mice fed with WPI had an unaltered stomach weight, suggesting that the reduction in 
260 stomach weight occurred between 7 to 15 weeks of WPI intake, after the reduction in intestinal  
261 length. These data together suggests a potential functional relationship between WPI induced 
262 changes in gastro-intestinal tract and energy intake. 
263 Organ development is in part regulated by the Wnt/β-catenin pathway involving Wnt 
264 proteins, Fzd and Lrp 5/6 receptor complexes, which interact and mediate effects through the β- 
265 catenin proteins
(20). Notably, Wnt5a has been shown to act independent of β-catenin pathway (the 
266 noncanonical signalling) but recent data suggest that it can also inhibit and stimulate the canonical 
267 Wnt/β-catenin by acting through the Ror2 receptor, which has been revealed by generation of  
268 transgenic mice over-expressing Wnt5a
(21)
 and by overexpression of Fzd4 and Lrp5 in 293cells, 
269 where the experimental manipulation allowed Wnt5a to stimulate Wnt/β-catenin signalling(22). 
270 Notably, mice ectopically expressing Wnt5a were stillborn and had reduced stomach and intestinal 
271 tracts
(21)
. Interestingly, targeted deletion of the Wnt5a gene in mice also caused changes in the 
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272 gastrointestinal tract
(23)
 similar to mice over-expressing the same gene
(21)
. Contrasting genetic 
273 manipulations of Wnt5a resulting in similar gastro-intestinal features in mice suggest a complex 
274 interplay between Wnt5a noncanonical signalling pathway and Wnt/β-catenin pathway. This 
275 complexity is further highlighted in the present study, as Wnt5a and Fzd4 gene expression  
276 decreased in the stomach in WPI fed mice compared to the controls, whilst the same genes in the 
277 ileum responded to the protein intake by increasing their expression, yet the two tissues reduced in 
278 weight. In contrast, neither were affected by WPI in the duodenum, with Ror2 and Lrp5 remaining 
279 unchanged throughout the gastro-intestinal tract where the gene expression was investigated. 
280 Importantly, this study demonstrates that Wnt signalling associated genes in the gastro-intestinal 
281 tract are responsive to WPI. We speculate that the regional specific expression and actions of Wnt5a 
282 and Fzd4 and associated inhibitory or stimulatory effects on the Wnt/β-catenin signalling pathway 
283 underlie the observed changes in the gastro-intestinal tract of WPI fed mice, which in turn modulate 
284 the energy intake and body weight gain. 
285 Although whey protein intake has been shown to cause an insulinotropic effect(24; 25), in the 
286 current study, WPI did not alter plasma levels of insulin, glucose or GLP-1, intestinal expression of 
287 GIP or insulin signalling associated genes in the liver, muscle or epididymal tissues. The lack of an 
288 insulinotropic effect could be due to the reduction in cumulative energy intake and associated  
289 reduced nutrient availability and/or due to the high sucrose content in the diet, which has previously 
290 been shown to cause glucose intolerance and impair GLP-1 secretion in mice
(26)
. Notably, IR 
291 expression in the duodenum showed a trend towards a decrease in response to WPI intake. Whether 
292 this related to the altered intestinal morphology remains to be determined because insulin action in 
293 the intestine has been shown to promote greater enterocyte turnover, which correlates with insulin- 
294 receptor expression in the villus-crypt axis
(27)
. 
295 In the current study there was a mismatch in the time frame of decreased cumulative energy 
296 intake and body weight gain as the former decreased by week 11, whilst the body weight gain was 
297 significantly different by week 12. Even at the end of the study, the plasma TAG level was not 
298 different between the two groups of mice, nor was percentage fat content in the body or specifically 
299 in the epididymal and subcutaneous fat pads. It is noteworthy in this respect that the epididymal 
300 expression of lipogenic ACC and FASN increased in association with a concurrent increased fatty 
301 acid transporter CD36 expression
(28)
. These data suggest an increased lipogenesis in the epididymal 
302 adipose tissue, which may be acting to maintain energy homeostasis causing a mismatch in the time 
303 frame between a decreased cumulative energy intake and body weight. In line with this suggestion, 
304 metabolic activity, which was measured at week 14, also decreased by WPI intake, presumably 
305 because of decreasing cumulative energy in mice with altered gastro-intestinal tracts. In contrast, in 
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306 our previous published studies, WPI at 20% energy content within a 45% energy fat diet reduced fat 
307 mass and normalised energy intake without affecting metabolic activity in mice at 8 and 21 weeks 
308 compared to casein fed control(4; 5) . In the latter studies, data for metabolic activity was shown 
309 relative to body weight (ml/hr/kg). In light of the suggestion that ANCOVA is a more suitable  
310 statistical method to identify effects of diet on metabolic activity independent of body weight  
311 changes, we re-analysed these previously published data using ANCOVA
(10)
. Again, as our 
312 previous published Vo2 data (in ml/hr/kg)
(4)
, there was not significant effect of WPI on Vo2 (ml/hr) 
313 independent of the body weight in the mice fed a high fat diet with WPI (data not shown). Thus, 
314 contrasting WPI effects on energy intake, fat mass and metabolic activity in the previously  
315 published studies(4; 5) compared to the present study could be related to how whey proteins affect 
316 energy balance in a background of altered fat to carbohydrate content in the diet. 
317 In conclusion, the results here show that 20% energy WPI in a 10% fat and 35% sucrose diet 
318 reduced cumulative energy intake, dark phase metabolic activity and body weight gain. This is  
319 accompanied by a decreased intestinal length and weight, as well as stomach weight, which was 
320 correlated with altered expression of Wnt signalling associated genes. Further investigations are 
321 required to determine the significance of the alteration to the intestinal environment uncovered here 
322 for energy balance regulation. 
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449 Figure legends 
450 Figure 1. Effect of whey protein isolate on energy balance related parameters. Mice were fed a 
451 10% kJ fat and 35%kJ sucrose diet with either 20% kJ casein (LF-CAS) or whey protein isolate 
452 (LF-WPI) for 15 weeks. The body weight trajectories over the 15 weeks are shown (A), together 
453 with weight gain (B), body composition (C) and cumulative energy intake over the first 13 weeks 
454 (D). Data represent means ± SEM (n = 8). * P < 0.05, ** P < 0.01. 
455 
456 Figure 2. Effect of whey protein isolate on tissue weights (A) and intestinal length (B). Mice 
457 fed a 10% kJ fat and 35%kJ sucrose diet with either 20% kJ casein (LF-CAS) or whey protein 
458 isolate (LF-WPI) for 15 weeks. Tissue weights are shown relative to casein fed animals. SAT, 
459 subcutaneous white adipose tissue; EAT, epididymal white adipose tissue. Data represent means ± 
460 SEM (n = 8). * P < 0.05, ** P < 0.01, ***P < 0.001. 
461 
462 Figure 3: Effect of whey protein isolate on gastro-intestinal Wnt gene expression. Mice were 
463 fed a 10% kJ fat and 35%kJ sucrose diet with either 20% kJ casein (LF-CAS) or whey protein 
464 isolate (LF-WPI) for 15 weeks, and the mRNA expression were measured in (A) stomach, (B)  
465 duodenum and (C) ileum. Gene expressions are shown relative to the LF-CAS group which was set 
466 at 1.00. Fzd4, Frizzled 4; Ror2, receptor tyrosine kinase-like orphan receptor 2; Lrp5, low density 
467 lipoprotein receptor-related protein 5. Data represent means ± SEM (n = 6-8). * P < 0.05, ** P < 
468 0.01. 
469 
470 Figure 4. Effect of whey protein isolate on epididymal adipose gene expression. Mice were fed 
471 a 10% kJ fat and 35%kJ sucrose diet with either 20% kJ casein (LF-CAS) or whey protein isolate 
472 (LF-WPI) for 15 weeks, and the mRNA expressions of epididymal adipose tissue genes were  
473 measured. Gene expressions are shown relative to the LF-CAS group which was set at 1.00. Genes 
474 investigated were insulin receptor (IR), glucose transporter 4, (GLUT4), insulin substrate 1 (IRS-1), 
475 βeta-3 adrenergic receptor (β3-AR), hormone sensitive lipase (HSL), carnitine palmitoyltransferase 
476 1b, (CPT1b), uncoupling protein 2 (UCP-2), peroxisome proliferator-activated receptor gamma 
477 (PPARγ), lipoprotein lipase (LPL), fatty acid transporter 1 (FATP1), cluster of differentiation 36 
478 (CD36), fatty acid synthase (FASN), and acetyl-CoA carboxylase (ACC). Data represent means ± 
479 SEM (n = 8). * P < 0.05, * * P < 0.01. 
480 
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481 Table 1 
482 Plasma parameters in mice fed a LF-CAS or LF-WPI diet for 15 weeks. 
  
 LF-CAS SEM LF-WPI SEM P value 
Plasma TAG (mg/dL) 36.18 1.42 33.68 2.59 NS 
Plasma leptin (ng/ml) 6.65 1.53 5.80 1.38 NS 
Plasma GLP-1 (pM) 24.70 3.50 23.59 1.50 NS 
Plasma glucose (mmol/L) 12.18 1.57 13.11 0.84 NS 
Plasma insulin (ng/ml) 0.21 0.01 0.22 0.01 NS 
HOMA-IR 3.07 0.39 3.12 0.16 NS 
 
483 Data are means ± SEM (n = 8). LF-CAS, 10%kJ fat and 35%kJ sucrose with 20%kJ casein; LF- 
484 WPI, 10%kJ fat and 35%kJ sucrose with 20%kJ whey protein isolate (WPI). GLP-1, glucagon-like 
485 peptide 1; HOMA-IR, homeostasis model assessment of insulin resistance; NS, not significant. 
486 
487 
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488 Table 2 
489 Metabolic parameters in mice fed a LF-CAS or LF-WPI diet at week 14. 
  
Phase LF-CAS SEM LF-WPI SEM P value 
Energy intake 
(kJ/mouse) 
Meal 
number 
Meal size 
(kJ) 
Water intake 
(ml/mouse) 
VO2 
(ml/hr) 
RER 
(VCO2 / VO2) 
Light 12.17 1.46 10.40 2.42 NS 
Dark 43.06 2.10 32.86 3.91 NS 
Light 13.0 1.1 20.3 5.0 NS 
Dark 31.9 2.9 25.4 3.0 NS 
Light 0.99 0.16 0.80 0.12 NS 
Dark 1.46 0.20 1.15 0.19 NS 
Light 0.61 0.10 0.82 0.22 NS 
Dark 2.83 0.32 3.65 0.69 NS 
Light 91.8 2.58 84.94 2.58 P=0.097 
Dark 104.83 1.54 98.74 1.54 P<0.05 
Light 0.83 0.01 0.82 0.03 NS 
Dark 0.98 0.01 0.92 0.02 NS  
490 Data are means ± SEM (n = 8). LF-CAS, 10%kJ fat and 35%kJ sucrose with 20%kJ casein; LF- 
491 WPI, 10%kJ fat and 35%kJ sucrose with 20%kJ whey protein isolate (WPI). NS; not significant; 
492 VO2, oxygen consumption; VCO2, Carbon dioxide consumption. 
493 
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Table 3 
Intestinal gene expression in mice fed a LF-CAS or LF-WPI diet for 15 weeks. 
 LF-CAS SEM LF-WPI SEM P value 
Duodenum      
IR 1.00 0.12 0.68 0.09 0.05 
GLUT2 1.00 0.09 0.94 0.06 NS 
IRS-1 1.00 0.09 0.84 0.07 NS 
SGLT-1 1.00 0.07 0.83 0.05 0.07 
CCK 1.00 0.05 0.76 0.15 NS 
GIP 1.00 0.10 0.65 0.15 NS 
FATP4 1.00 0.06 1.13 0.13 NS 
Ileum 
     
IR 1.00 0.04 1.00 0.07 NS 
GLUT2 1.00 0.21 1.89 0.31 <.05 
IRS-1 1.00 0.06 1.13 0.17 NS 
SGLT-1 1.00 0.09 0.99 0.10 NS 
Proglucagon 1.00 0.07 1.13 0.17 NS 
PYY 1.00 0.11 0.60 0.06 <.01 
FATP4 1.00 0.08 0.77 0.04 <.05 
 
Data are means ± SEM (n = 6-8). Values that differ significantly if P < 0.05; NS, non-
significant. LF-CAS, 10%kJ fat and 35%kJ sucrose diet with 20%kJ casein; LF-WPI, 
10%kJ fat and 35%kJ sucrose diet with 20%kJ whey protein isolate (WPI). Gene 
expressions are shown relative to the LF-CAS group which was set at 1.00. IR, Insulin 
receptor, GLUT2, Glucose transporter 2; IRS-1, Insulin receptor substrate 1; SGLT-1, 
Sodium-glucose co-transporter 1; CCK, Cholecystokinin; GIP, Glucose-dependent 
insulinotrophic peptide; PYY, Peptide YY; FATP4, Fatty acid transport protein 4. 
  
 
LF-WPI LF-CAS 
0  L F - C A S  
LF-WPI 
 
D  6 _  O  LF - C AS  
LF-WPI 
 OT, _____________________  
 0 3 6 9 1 2  1 5  
 Weeks 
8- 
3  6 "  
i 
(-9 4- 
2- 
Lean mass Fat mass 
** 
* 
I  I   
9 11 
Weeks 
-T- 
7 
Figure 1 
A 28 - 
26 - 
6) 24- 
 22- 
20- 
 18- 
 16- 
0- 
0- 
LF-CAS 
LF-WPI 
0 
  
 
B 40-  
  *** 
 35-  
—I-1  
30- 
  
(U =    
E-    
 25   
 0   
LF-CAS LF-WPI 
figure 2 
A 1.4- 1=1 LF-CAS 
LF-WPI 
 
0.0 T I 
 Figure 3 
= LF-CAS 
• LF-WPI 
1.5- 
 
0.0 
Wnt5a Ror2 Fzd4 Lrp5 
 
B 
1.5- 
1.0- 
0.5- 
0.0 
Wnt5a Ror2 Fzd4 Lrp5 
r 1 
-T- I _L _T_ _r_ 
Wnt5a Ror2 Fzd4 Lrp5 
A 
C 
2.0- 
 
0.0 
 w 1.5- 
Figure 4 
2 .5 -  o  L F- C AS  
LF-WPI 
 4 1 . 0 A 4 4 1 1 1 4 [ 1 1 [ 1 1 4 4 4 1 1 i  
** 
 r
-
I 
 w 0_ ______________________ 0 .   (i) 
1-
 o_ r> I- i- 0 (-) 0_ -- 
0 U a u_ 
 Supplementary table 1: Composition of the experimental diets 
Contents (g) LF-CAS LF-WPI 
Casein 200 0 
WPI (>98% dry basis) 0 200 
L-Cystine 3 3 
Corn Starch 315 315 
Maltodextrin 10 35 35 
Sucrose 350 350 
Cellulose, BW200 50 50 
Soybean oil 25 25 
Lard 20 20 
Mineral mix S10026A 10 10 
CaHPO4 13 13 
CaCO3 5.5 5.5 
C5H6K3O7.1H2O 16.5 16.5 
Vitamin mix V10001 10 10 
Choline Bitartrate 2 2 
Energy (kcal/g) 3.8 3.8 
Protein (% kcal) 20 20 
Carbohydrate (% kcal) 70 70 
Fat(%kcal) 10 10 
 
Diets formulated and produced by Research Diets Inc. (New Brunswick, NJ, USA) 
LF, low fat diet; CAS, casein protein; WPI, whey protein isolate. 
 Supplementary table 2. Sequences of mouse specific primers used in real-time PCR analysis 
Forward primer (5 ’-3’) Reverse primer (5 ’-3’) 
Acetyl-CoA carboxylase (ACC) 5 ’-tgttgagacgctggtttgtagaa-3’ 5 ’-ggtccttattattgtcccagacgta-3’ 
Beta-3 adrenergic receptor (β3-AR) 5 ’-cgccttcaacccggtcatctactg-3’ 5 ’-ggtggactctgcctggcttcaac-3’ 
Cluster of differentiation 36 (CD36) 5 ’-tgatactatgcccgcctctcc-3’ 5 ’-tttcccacactcctttctcctcta-3’ 
Carnitine palmitoyltransferase 1 a (CPT1 a) 5 ’-agacttccaacgcatgacagcactg-3’ 5 ’-ctcggccccgcaggtagatg-3’ 
Carnitine palmitoyltransferase 1b (CPT1b) 5 ’-cgagaggggcggactgagactg-3’ 5 ’-ggctaggcggtacatgttttggtg-3’ 
Cholecystokinin (CCK) 5 ’-gtgccgaggactacgaatacc-3’ 5 ’-tctgggagtcactgaaggaaacac-3’ 
Fatty acid synthase (FASN) 5 ’-tccacctttaagttgccctg-3’ 5 ’-tctgctctcgtcatgtcacc-3’ 
Fatty acid transport protein 1 (FATP1) 5 ’-ccggtgtggtggctgctcttctc-3’ 5 ’-gctgccatctccccgccataaatg-3’ 
Fatty acid transport protein 4 (FATP4) 5 ’-tggcgtttcatccgggtcttcatc-3’ 5 ’-gcaaacagcaggggcaccgtcttc-3’ 
Frizzled-4 (Fzd4) 5 ’-gctgactgtaggccgggaaagg-3’ 5 ’-cggctgccaaaaaccaagtgag-3’ 
Glucose-dependent insulinotropic peptide 5’-tctctgttgctggtgctcctgttc-3’ 5 ’-gctctcctgtgcctctttgtcctc-3’ 
(GIP) 
Glucose transporter 2 (GLUT2) 5 ’-tcctacttggcctatctgctgtgc-3’ 5 ’-tgccctgacttcctcttccaac-3’ 
Glucose transporter 4 (GLUT4) 5’-ggcctgcccgaaagagtc-3’ 5’-aggagctggagcaaggac-3’ 
Hormone sensitive lipase (HSL) 5’-ctattcagggacagaggcag-3’ 5’-cgatgtggtcttttggggc-3’ 
Insulin receptor (IR) 5 ’-gatttccccaacgtgtcctctac-3’ 5 ’-caatgcggtacccagtgaagtg-3’ 
Insulin receptor substrate 1 (IRS-1) 5’-gcgcaggcaccatctcaacaacc-3’ 5’-gcacgcacccggaaggaacc-3’ 
Leptin 5 ’-ccccgcaccgctggaagtac-3’ 5 ’-atgtgccctgaaatgcggtatg-3’ 
Lipoprotein lipase (LPL) 5 ’-tgctcccaacaatataagactcc-3’ 5 ’-aaggccaggtgtttcaatc-3’ 
Lipoprotein-receptor related protein 5 5’ -cccgccctccaccttcttgctg-3’ 5’-accgtcgtccttggccctcttgatg-3’ 
(Lrp5) 
Peroxisome proliferator-activated 
receptor5’-tcaggtttgggcggatgc-3’ 5’-tcagcgggaaggactttatgtatg-3’ 
γ (PPARγ) 
Peptide YY 5 ’-ggacgcctaccctgccaaacca-3’ 5 ’-agtgccctcttcttaaaccaaaca-3’ 
Pro-glucagon 5 ’-agggacctttaccagtgatgtga-3’ 5 ’-acgagatgttgtgaagatggttgt-3’ 
Receptor tyrosine kinase-like orphan 5’ -tggacggcaggtgaagtgg-3’ 5’-gtctggccctgaacaatggtgata-3’ 
receptor (Ror2) 
Sodium-glucose co-transporter 1 (SGLT-1) 5 ’-gagccccgcggttactgc-3’ 5 ’-cctgcggctgctcctgtg-3’ 
Uncoupling protein 2 (UCP-2) 5 ’-ccatttcctgcaccccgatttacttcc-3’ 5 ’-gctgggctggggatgaagatgaag-3’ 
Uncoupling protein 3 (UCP-3) 5 ’-acaggcccacacggtccagaacc-3’ 5 ’-cccatcaggtcagtgcaaaacagagg-3’ 
Wnt5a 5 ’-cctgcctcgggactggttgtg-‘3 5 ’-cctacggcctgcttcattgttgtg-3’ 
β-actin 5 ’-agagggaaatcgtgcgtgac-3’ 5 ’-caatagtgatgacctggccgt-3’ 
18-S 5 ’-aggaccgcggttctattttgttgg-3’ 5 ’-atgctttcgctctggtccgtcttg-3’ 
YWHAZ 5 ’-cggagctgcgtgacatctgc-3’ 5 ’-cctcggccaagtaacggtagtag-3’ 
 Supplementary table 3: Skeletal muscle gene expression in mice fed a LF-CAS or LF-WPI diet 
for 15 weeks. 
 LF-CAS SEM LF-WPI SEM P value 
IR 1.00 0.19 1.01 0.08 NS 
GLUT4 1.00 0.10 0.82 0.05 NS 
IRS-1 1.00 0.08 0.81 0.04 0.06 
CPT1b 1.00 0.13 0.85 0.06 NS 
UCP-3 1.00 0.17 0.94 0.09 NS 
LPL 1.00 0.14 0.87 0.16 NS 
ACC 1.00 0.43 0.62 0.21 NS 
CD36 1.00 0.14 1.05 0.15 NS 
Data are means ± SEM (n = 8). Values differ significantly if P < 0.05; NS, non-significant. LF-
CAS, 10% kJ fat, 35%kJ sucrose with 20%kJ casein protein; LF-WPI, 10% kJ fat, 35%kJ sucrose 
with 20%kJ whey protein isolate (20% kJ). Gene expressions are shown relative to the LF-CAS 
group which was set at 1.00. IR, Insulin receptor; GLUT4, Glucose transporter 4; IRS-1, Insulin 
receptor substrate 1; CPT1b, Carnitine palmitoyltransferase 1b; UCP-3, Uncoupling protein 3; LPL, 
Lipoprotein lipase; ACC, Acetyl-CoA carboxylase; CD36, Cluster of differentiation 36. 
 Supplementary table 4: Liver gene expression in mice fed a LF-CAS or LF-WPI diet for 15 
weeks. 
 LF-CAS SEM LF-WPI SEM P value 
GLUT2 1.00 0.12 1.03 0.09 NS 
IRS-1 1.00 0.12 0.93 0.06 NS 
CPT1a 1.00 0.18 1.08 0.12 NS 
UCP-2 1.00 0.07 1.07 0.08 NS 
FASN 1.00 0.29 0.96 0.12 NS 
ACC 1.00 0.14 1.10 0.14 NS 
LPL 1.00 0.09 0.96 0.07 NS 
CD36 1.00 0.20 0.92 0.07 NS 
 
Data are means ± SEM (n = 7-8). Values that differ significantly if P < 0.05; NS, non-significant. 
LF-CAS, 10% kJ fat, 35%kJ sucrose with 20%kJ casein protein; LF-WPI, 10% kJ fat, 35%kJ 
sucrose with 20%kJ with whey protein isolate (20% kJ). Gene expressions are shown relative to the 
LF-CAS group which was set at 1.00. GLUT2, Glucose transporter 2; IRS-1, Insulin receptor 
substrate 1; CPT1a, Carnitine palmitoyltransferase 1a; UCP-2, Uncoupling protein 2; FASN, Fatty 
acid synthase; ACC, Acetyl-CoA carboxylase; LPL, Lipoprotein lipase; CD36, Cluster of 
differentiation 36 
